...
首页> 外文期刊>Molecular biology reports >Development of ARMS-PCR assay for genotyping of Pro12Ala SNP of PPARG gene: a cost effective way for case-control studies of type 2 diabetes in developing countries
【24h】

Development of ARMS-PCR assay for genotyping of Pro12Ala SNP of PPARG gene: a cost effective way for case-control studies of type 2 diabetes in developing countries

机译:开发用于PPARG基因Pro12Ala SNP基因分型的ARMS-PCR分析法:在发展中国家进行2型糖尿病病例对照研究的一种经济有效的方法

获取原文
获取原文并翻译 | 示例
           

摘要

Type 2 diabetes (T2D) is a prevalent metabolic disorder across the globe. Research is underway on various aspects including genetics to understand and control the global epidemic of diabetes. Recently, several SNPs in various genes have been associated with T2D. These association studies are mainly carried out in the developed countries through Genome Wide Association Scans, with follow-up replication/validation studies by high-throughput genotyping techniques (e.g. Taqman Technology). Although, similar studies could be conducted in developing countries, however, the limiting factors are the associated cost and expertise. These factors hamper research into the genetic association and replication studies from low-income countries to figure out the role of putatively associated SNPs in diabetes. Although, there are several SNP detection methods (e.g. Taqman assay, Dot-blot, PCR-RFLP, DGGE, SSCP) but these are either expensive or labor intensive or less sensitive. Hence, our aim was to develop a low-cost method for the validation of PPARG (Pro12Ala, CCA > GCA) SNP (rs1801282) for its association with T2D. Here, we developed a cost-effective and rapid amplification refractory mutation specific-PCR (ARMS-PCR) method for this SNP detection. We successfully genotyped PPARG SNPs (Pro12Ala) in human samples and the validity of this method was confirmed by DNA sequencing of a few representative samples for the three different genotypes. Furthermore, ARMS-PCR was applied to T2D patients and control samples for the screening of this SNP.
机译:2型糖尿病(T2D)是全球范围内普遍存在的代谢性疾病。正在进行包括遗传学在内的各个方面的研究,以了解和控制全球糖尿病的流行。最近,各种基因中的几个SNP已与T2D相关。这些关联研究主要在发达国家通过全基因组关联扫描进行,并通过高通量基因分型技术(例如Taqman Technology)进行后续的复制/验证研究。尽管可以在发展中国家进行类似的研究,但是,限制因素是相关的成本和专业知识。这些因素阻碍了对来自低收入国家的基因关联和复制研究的研究,从而无法确定假定相关的SNP在糖尿病中的作用。尽管有几种SNP检测方法(例如Taqman分析,斑点印迹,PCR-RFLP,DGGE,SSCP),但这些方法要么昂贵,要么劳动强度大或敏感性较低。因此,我们的目标是开发一种低成本的方法来验证PPARG(Pro12Ala,CCA> GCA)SNP(rs1801282)与T2D的关联。在这里,我们为这种SNP检测开发了一种经济高效的快速扩增难治性突变特异性PCR(ARMS-PCR)方法。我们成功地对人类样品中的PPARG SNPs(Pro12Ala)进行了基因分型,并且该方法的有效性通过对三种不同基因型的一些代表性样品进行DNA测序证实。此外,将ARMS-PCR应用于T2D患者和对照样品以筛选该SNP。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号